Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them

Savage, Kerry J.

doi:10.1080/17474086.2016.1242404

Cited by 9 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, significant results with checkpoint inhibition approaches have yielded regulatory approvals of novel drugs and combination regimens, leading to new standards of care for patients with RCC, non-small cell lung cancer (NSCLC) [12], small cell lung cancer (SCLC) [13], bladder cancer [14], Merkel cell cancer [15], head and neck cancer [16], gastrointestinal cancer [17]and certain lymphomas [18]. Investigators are motivated by early success in identifying potential predictive biomarkers to select patients most likely to benefit (including programmed death ligand-1 or PDL1, and micro-satellite instability high or MSI-Hi), as checkpoint inhibition strategies are yielding even higher response rates in some tumors [19, 20].…”

Section: Introduction: Current Clinical Landscapementioning

confidence: 99%

The promise of Immuno-oncology: implications for defining the value of cancer treatment

Kaufman¹,

Atkins²,

Subedi³

et al. 2019

j. immunotherapy cancer

View full text Add to dashboard Cite

The rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer. Responding to ongoing efforts to generate value assessments for novel therapies, multiple stakeholders have been considering the question of “What makes I-O transformative?” Evaluating the distinct features and attributes of these therapies, and better characterizing how patients experience them, will inform such assessments. This paper defines ways in which treatment with I-O is different from other therapies. It also proposes key aspects and attributes of I-O therapies that should be considered in any assessment of their value and seeks to address evidence gaps in existing value frameworks given the unique properties of patient outcomes with I-O therapy. The paper concludes with a “data needs catalogue” (DNC) predicated on the belief that multiple key, unique elements that are necessary to fully characterize the value of I-O therapies are not routinely or robustly measured in current clinical practice or reimbursement databases and are infrequently captured in existing research studies. A better characterization of the benefit of I-O treatment will allow a more thorough assessment of its benefits and provide a template for the design and prioritization of future clinical trials and a roadmap for healthcare insurers to optimize coverage for patients with cancers eligible for I-O therapy.

show abstract

Section: Introduction: Current Clinical Landscapementioning

confidence: 99%

The promise of Immuno-oncology: implications for defining the value of cancer treatment

Kaufman¹,

Atkins²,

Subedi³

et al. 2019

j. immunotherapy cancer

View full text Add to dashboard Cite

show abstract

“…This is further supported by findings in recent studies evaluating the highly successful checkpoint inhibitors, which have shown that PD-1 blockade acts by promoting T-cell activation. 31 Biomarkers for response to checkpoint inhibitors in HL remain elusive, 32 and this will be evaluated in future studies.…”

Section: Discussionmentioning

confidence: 99%

Flow cytometry for assessment of the tumor microenvironment in pediatric Hodgkin lymphoma

Henry

Buck

Savaşan

2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…The motivation for adopting ICIs in the treatment of lymphoma relies on the existence in such malignancies of mechanisms that escape immune surveillance due to genetic variance. These agents may re-educate cells in the microenvironment, restoring chemokine and cytokine signaling as well as expression of checkpoint proteins (56,(60)(61)(62)(63)(64)(65)(66). They are able to block the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) pathways.…”

Section: Immune Checkpoint Inhibitors (Icis)mentioning

confidence: 99%

“…Nivolumab, a completely humanized IgG4 anti-PD-1 mAB, is now approved for melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma. The activity of nivolumab in lymphoid malignancies has also been widely tested (60,61,66,68,77). Patients with recurrent B-cell NHL were treated at the identical schedule with dose escalation of 1-3 mg/kg of nivolumab.…”

Section: Immune Checkpoint Inhibitors (Icis)mentioning

confidence: 99%

Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

et al. 2019

View full text Add to dashboard Cite

The improved knowledge of pathogenetic mechanisms underlying lymphomagenesis and the discovery of the critical role of tumor microenvironments have enabled the design of new drugs against cell targets and pathways. The Food and Drug Administration (FDA) has approved several monoclonal antibodies (mAbs) and small molecule inhibitors (SMIs) for targeted therapy in hematology. This review focuses on the efficacy results of the currently available targeted agents and recaps the main ongoing trials in the setting of mature B-Cell non-Hodgkin lymphomas. The objective is to summarize the different classes of novel agents approved for mature B-cell lymphomas, to describe in synoptic tables the results they achieved and, finally, to draw future scenarios as we glimpse through the ongoing clinical trials. Characteristics and therapeutic efficacy are summarized for the currently approved mAbs [i.e., anti-Cluster of differentiation (CD) mAbs, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and bispecific antibodies] as well as for SMIs i.e., inhibitors of B-cell receptor signaling, proteasome, mTOR BCL-2 HDAC pathways. The biological disease profiling of B-cell lymphoma subtypes may foster the discovery of innovative drug strategies for improving survival outcome in lymphoid neoplasms, as well as the trade-offs between efficacy and toxicity. The hope for clinical advantages should carefully be coupled with mindful awareness of the potential pitfalls and the occurrence of uneven, sometimes severe, toxicities.

show abstract

Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them

Cited by 9 publications

References 32 publications

The promise of Immuno-oncology: implications for defining the value of cancer treatment

The promise of Immuno-oncology: implications for defining the value of cancer treatment

Flow cytometry for assessment of the tumor microenvironment in pediatric Hodgkin lymphoma

Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

Contact Info

Product

Resources

About